文献速递血液净化与透析

美国透析患者的结肠癌筛查:我们是否在明智选择?

Colon Cancer Screening among Patients Receiving Dialysis in the United States: Are We Choosing Wisely?
PubMed 文献 · J Am Soc Nephrol · 2017-03-23

美国肾脏病学会基于有限的生存获益,不建议对无症状的维持性透析患者进行常规癌症筛查。该队列研究纳入2007年1月1日至2012年9月30日期间接受透析的469,574例年龄≥50岁的医疗保险受益人,评估结直肠癌筛查的频率及筛查是否针对死亡风险较低和接受肾移植可能性较高的患者。中位随访1.5年期间,11.6%的患者接受了结肠癌筛查(每1000人年57.9次检测);死亡风险最低四分位组患者比最高四分位组更可能接受筛查(风险比1.53;95%置信区间1.49至1.57;分别为每1000人年65.1次 vs 46.4次检测),相当于检测率高出33%;移植可能性最高的患者比最低的患者更可能接受筛查(风险比1.68;95%置信区间1.64至1.73)。结肠癌筛查正针对死亡风险最低和移植可能性最高的透析患者,但绝对筛查率较高,提示过度筛查。

要点

  • 美国肾脏病学会不建议对无症状的维持性透析患者进行常规癌症筛查。
  • 中位随访1.5年,11.6%的透析患者接受了结肠癌筛查(每1000人年57.9次检测)。
  • 死亡风险最低四分位组比最高四分位组更可能接受筛查(风险比1.53;95%置信区间1.49至1.57),检测率高出33%。

核心结论

  • 结肠癌筛查正针对死亡风险最低和移植可能性最高的透析患者,但绝对筛查率较高,提示过度筛查。

研究设计与样本

  • 队列研究,纳入2007年1月1日至2012年9月30日期间接受透析的469,574例年龄≥50岁的美国医疗保险受益人。
  • 根据多变量Cox模型,按死亡风险和肾移植可能性四分位数分析结直肠癌筛查检测。

主要发现

  • 中位随访1.5年,11.6%的患者接受了结肠癌筛查检测(每1000人年57.9次检测)。
  • 结肠镜检查、软式乙状结肠镜检查和粪便隐血试验的发生率分别为每1000人年27.9、0.6和29.5次。
  • 死亡风险最低四分位组比最高四分位组更可能接受筛查(风险比1.53;95%置信区间1.49至1.57;分别为每1000人年65.1次 vs 46.4次检测),相当于检测率高出33%。
  • 移植可能性最高的患者比移植可能性最低的患者更可能接受筛查(风险比1.68;95%置信区间1.64至1.73)。

关键数值与推荐

  • 美国肾脏病学会基于有限的生存获益,不建议对无症状的维持性透析患者进行常规癌症筛查。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The American Society of Nephrology recommends against routine cancer screening among asymptomatic patients receiving maintenance dialysis on the basis of limited survival benefit. To determine the frequency of colorectal cancer screening among patients on dialysis and the extent to which screening tests were targeted toward patients at lower risk of death and higher likelihood of receiving a kidney transplant, we performed a cohort study of 469,574 Medicare beneficiaries ages ≥50 years old who received dialysis between January 1, 2007 and September 30, 2012. We examined colorectal cancer screening tests according to quartiles of risk of mortality and kidney transplant on the basis of multivariable Cox modeling. Over a median follow-up of 1.5 years, 11.6% of patients received a colon cancer screening test (57.9 tests per 1000 person-years). Incidence rates of colonoscopy, flexible sigmoidoscopy, and fecal occult blood test were 27.9, 0.6, and 29.5 per 1000 person-years, respectively. Patients in the lowest quartile of mortality risk were more likely to be screened than those in the highest quartile (hazard ratio, 1.53; 95% confidence interval, 1.49 to 1.57; 65.1 versus 46.4 tests per 1000 person-years, respectively), amounting to a 33% higher rate of testing. Additionally, compared with patients least likely to receive a transplant, patients most likely to receive a transplant were more likely to be screened (hazard ratio, 1.68; 95% confidence interval, 1.64 to 1.73). Colon cancer screening is being targeted toward patients on dialysis at lowest risk of mortality and highest likelihood of transplantation, but absolute rates are high, suggesting overscreening.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Carlos CA, McCulloch CE, Hsu CY, et al. Colon Cancer Screening among Patients Receiving Dialysis in the United States: Are We Choosing Wisely? J Am Soc Nephrol. 2017. PMID: 28336719. doi:10.1681/ASN.2016091019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。